Literature DB >> 3373314

Reappraisal of the baseline bone scan in breast cancer.

R E Coleman1, R D Rubens, I Fogelman.   

Abstract

Baseline staging bone scans in 1,267 consecutive women with breast cancer attending a single clinic between 1980 and 1986 were reviewed. 0.3% of patients with T1, 3% with T2, 8% with T3, 13% with T4 tumors and none of those with Stage 1, 3% with Stage 2, 7% with Stage 3, and 47% with Stage 4 disease had a positive scan due to bone metastases. Two hundred eight-nine (23%) had bone scan abnormalities secondary to radiologically confirmed benign bone disease. In 20 patients, no cause for a bone scan abnormality could be found after a median follow-up of 3.50 yr, a false-positive frequency of 1.6%. The false-negative rate was 0.08%. It is concluded that patients with tumors less than 2 cm are most unlikely to have a positive scan. In this instance, scans are not required routinely. However, we recommend a baseline scan in all patients with Stage 2, 3, or 4 disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3373314

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

Review 1.  Management of early breast cancer.

Authors:  R D Rubens
Journal:  BMJ       Date:  1992-05-23

2.  A Comparative Study of Bone Scan Findings and Serum Levels of Tumor Marker CA15-3 in Patients with Breast Carcinoma.

Authors:  Meera S Ghadge; Purva P Naik; Bijaynath P Tiwari; Ruprekha M Hegde; Tanaji J Matale
Journal:  Indian J Clin Biochem       Date:  2011-09-30

3.  Baseline staging tests in primary breast cancer: a practice guideline.

Authors:  R E Myers; M Johnston; K Pritchard; M Levine; T Oliver
Journal:  CMAJ       Date:  2001-05-15       Impact factor: 8.262

4.  A prospective study of bone tumor response assessment in metastatic breast cancer.

Authors:  Naoki Hayashi; Colleen M Costelloe; Tsuyoshi Hamaoka; Caimiao Wei; Naoki Niikura; Richard L Theriault; Gabriel N Hortobagyi; John E Madewell; Naoto T Ueno
Journal:  Clin Breast Cancer       Date:  2012-10-24       Impact factor: 3.225

5.  CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients.

Authors:  D P O'Brien; P G Horgan; D B Gough; R Skehill; H Grimes; H F Given
Journal:  Ann R Coll Surg Engl       Date:  1992-01       Impact factor: 1.891

6.  Analysis of clinicopathological factors associated with bone metastasis in breast cancer.

Authors:  Jing Chen; Shu Zhu; Xiu-Zhen Xie; Shan-Feng Guo; Liang-Qian Tong; Sheng Zhou; Ming Zhao; Zhi-Qun Xianyu; Xiao-Hua Zhu; Wei Xiong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-02-08

7.  Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer.

Authors:  Vidija Soerdjbalie-Maikoe; Rob C M Pelger; Guus A B Lycklama à Nijeholt; Jan-Willem Arndt; Aeilko H Zwinderman; Herman Bril; Socrates E Papapoulos; Neveen A T Hamdy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-19       Impact factor: 9.236

8.  An open cohort study of bone metastasis incidence following surgery in breast cancer patients.

Authors:  Mitsuru Koizumi; Masataka Yoshimoto; Fujio Kasumi; Takuji Iwase
Journal:  BMC Cancer       Date:  2010-07-21       Impact factor: 4.430

9.  Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer.

Authors:  T Hamaoka; C M Costelloe; J E Madewell; P Liu; D A Berry; R Islam; R L Theriault; G N Hortobagyi; N T Ueno
Journal:  Br J Cancer       Date:  2010-01-26       Impact factor: 7.640

10.  Surgery triggers outgrowth of latent distant disease in breast cancer: an inconvenient truth?

Authors:  Michael Retsky; Romano Demicheli; William Hrushesky; Michael Baum; Isaac Gukas
Journal:  Cancers (Basel)       Date:  2010-03-30       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.